Xue, K
Groppe, M
Salvetti, A P
MacLaren, R E
Article History
Received: 31 December 2016
Accepted: 3 July 2017
First Online: 18 August 2017
Competing interests
: REM: a founding director of NightstaRx (London, UK)—a gene therapy company established by the University of Oxford and funded by the Wellcome Trust. REM is a named inventor on a patent ‘Vector administration and dosing’ filed on behalf of the University of Oxford (US Patent Application No. 14/598,948). The remaining authors declare no conflict of interest.